Keytruda Gains 40th FDA Approval for Advanced Endometrial Cancer Treatment
Key Insights
Pembrolizumab (Keytruda) secured its 40th FDA approval, combined with chemotherapy, for treating primary advanced or recurrent endometrial cancer (search) in adults.
The approval was based on Phase 3 NRG-GY018 trial data, demonstrating a 70% reduction in disease progression risk with pembrolizumab and chemotherapy.
Endometrial cancer (search) is projected to become the third-most prevalent cancer in women by 2040, highlighting the importance of this new treatment option.
Merck (search)'s Keytruda (pembrolizumab) has achieved its 40th FDA approval, marking a significant advancement in endometrial cancer (search) treatment. The FDA approved Keytruda in combination with chemotherapy for adult patients with primary advanced or recurrent endometrial cancer on June 17. This approval is based on the Phase 3 NRG-GY018 (KEYNOTE-868) trial, which demonstrated a substantial reduction in disease progression risk.
Clinical Trial Data
The Phase 3 NRG-GY018 trial, also known as KEYNOTE-868, revealed that patients treated with pembrolizumab and chemotherapy experienced a 70% lower risk of disease progression compared to those receiving chemotherapy alone. These findings, published in the New England Journal of Medicine, underscore the clinical benefit of integrating Keytruda into the treatment regimen for advanced endometrial cancer (search).
Mechanism of Action
Keytruda is a monoclonal antibody that targets the PD-1 (search) protein on immune T cells, effectively blocking the PD-1/PD-L1 signaling pathway. This mechanism enhances the anti-tumor immune response by unleashing the immune system to eradicate tumors. Originally invented by scientists at Organon in 2006 before Merck (search) acquired the company, Keytruda has become a cornerstone in cancer immunotherapy.
Endometrial Cancer Burden
Endometrial cancer (search) is an increasingly prevalent disease with rising mortality rates. Projections indicate that it will become the third-most common cancer and the fourth-leading cause of cancer-related deaths in women by 2040. This approval addresses a critical unmet need in the treatment landscape for this disease.
Keytruda's Expanding Role
In addition to this recent approval, Keytruda is also approved for treating advanced endometrial cancer (search) in adult patients who have not responded to prior treatments and are not candidates for surgery or radiation. Its versatility has led to approvals across a spectrum of cancers, including melanoma (search), non-small cell lung cancer (search) (NSCLC), liver, colorectal (search), and triple-negative breast cancer. Keytruda's inclusion on the World Health Organization’s list of essential medicines reflects its global impact and importance.
Ongoing Research
Numerous clinical trials are currently underway to evaluate Keytruda's efficacy, both as a monotherapy and in combination with other treatments, across various cancer types. These ongoing investigations aim to further expand Keytruda's therapeutic potential and improve outcomes for patients with cancer.